Table 4 Cumulative incidence of the most common treatment-emergent adverse events during double-blind monotherapy treatment up to 2.2 years

Adverse event% Patientsp Value*
25/50 mg Topiramate (n = 125)200/500 mg Topiramate (n = 127)
Reported by ≥10% of patients in either topiramate dosage group. Includes adverse events from beginning of open-treatment phase.
* Two-sided.
Paresthesia1335<0.0001
Headache24190.323
Fatigue17180.784
Somnolence14170.514
Weight loss6150.026
Nausea10130.584
Dizziness19120.104
Diarrhea5120.042
Anorexia8100.537
Hypoesthesia5100.100
Upper respiratory tract infection20100.029